What changed in the 2025 obesity definition

Change one: BMI needs a confirming measure

The Commission concluded what body-composition research had shown for years: BMI is a screening proxy, not a measure of body fat, and it misclassifies in both directions: muscular people flagged high, people with excess visceral fat waved through. The new criteria require BMI plus at least one direct indicator of fat distribution: waist circumference against the WHO thresholds, waist-to-hip ratio, or waist-to-height ratio. (At BMI 40+, the probability of excess adiposity is high enough that BMI alone is accepted.)

This is the check the form above runs. Raised BMI with a raised distribution measure meets the anthropometric criteria; raised BMI with normal distribution measures is discordant (the athlete pattern) and does not.

The criteria, set out

The Commission offered four routes to confirming excess adiposity rather than one, which is the detail most summaries lose. BMI is only one of them, and two of the four do not involve BMI at all. The thresholds below are the ones used for adults of European descent; the Commission is explicit that population-specific values apply elsewhere, which for most Asian populations means a lower waist threshold and, in several national systems, a lower BMI threshold too.

Notice what the second route means in practice. Someone with a BMI of 23 and both a waist circumference and a waist-to-height ratio above their thresholds meets the anthropometric criteria under this framework, even though no BMI-based system would have flagged them. That is the change cutting in the direction people rarely mention, and it is the more consequential half.

Change two: preclinical versus clinical obesity

The second shift is conceptual. Excess adiposity with organs functioning normally is now preclinical obesity, a state of elevated future risk, warranting monitoring and support, but not itself a disease. Excess adiposity that is already impairing organ function (evidenced by things like breathlessness, heart failure signs, metabolic dysfunction, joint disease attributable to the adiposity) is clinical obesity, a standalone chronic illness warranting treatment in its own right.

That distinction requires clinical assessment: history, examination, blood work. No website can make it, and this one doesn't pretend to. What the calculator tells you is whether the anthropometric screen is met; whether that is preclinical or clinical is a conversation between you and a doctor. The Commission's own hope was to end both under-treatment of people whose obesity is already an illness and over-labelling of people whose bodies are simply large.

What counts as clinical obesity

The Commission did not leave 'organ dysfunction' as a vague phrase. It set out eighteen specific diagnostic criteria for clinical obesity in adults, each describing a sign, symptom or functional limitation that can be attributed to excess adiposity rather than merely coexisting with it. That attribution is the hard part and the reason this cannot be done from a form: knee pain in someone with a high BMI might be obesity-related, or might be an old sports injury, and only assessment can tell.

The examples below are drawn from the Commission's own criteria. They are illustrative of the categories rather than the full list, and none of them is something to self-diagnose from a web page. They are here so you can see what kind of evidence the framework is asking for.

• Breathlessness caused by the effect of excess fat on the lungs and chest wall.
• Obesity-induced heart failure.
• Knee or hip pain with joint stiffness and reduced range of motion, directly attributable to excess body fat loading the joint.
• Metabolic dysfunction: the combination of raised blood glucose with abnormal lipids that excess adiposity drives.
• Signs and symptoms arising from dysfunction of other organ systems: kidneys, upper airway, liver, and the nervous, urinary and reproductive systems.
• Lymphoedema of the lower limbs attributable to the adiposity.
• Objectively reduced ability to carry out standard day-to-day activities such as bathing, dressing, eating or toileting.

Who endorsed it, and where it is being adopted

The report carried unusually broad institutional weight for a definitional paper. More than 75 medical organisations endorsed it, among them the World Obesity Federation, the American Diabetes Association, the American Heart Association, The Obesity Society and the Association of British Clinical Diabetologists, spanning endocrinology, cardiology, surgery, primary care and public health. The Commission itself included people living with obesity alongside the clinicians and researchers, which is not the usual composition for a document of this type.

Endorsement is not the same as implementation, and that gap is the honest caveat. A definition changes practice when it reaches coding systems, referral criteria, drug and surgery eligibility rules and insurance schedules, and those move at the pace of national health bureaucracies rather than journals. Expect several years of overlap in which the new framework is the stated standard and BMI-alone thresholds are still what gate access to things.

Adoption has started, though. India published a revised national definition of obesity for Asian Indians in 2025 built on the same two-stage logic: stage 1 is raised adiposity without effect on organ function or daily activities, and stage 2 requires a raised waist-based measure together with an obesity-related condition or a functional limitation. Japan's JASSO framework has drawn a comparable distinction for years through its 'obesity disease' concept, which requires a related health disorder or a visceral fat area of at least 100 cm² before obesity is treated as a condition to manage.

What happens at the doctor

The anthropometric part is quick and you can arrive with most of it done. Height, weight and a waist measurement take a couple of minutes; a waist-to-hip ratio adds one more tape pass. If you bring your own waist measurement, say how you took it (the landmark you used and whether you measured on skin at the end of a normal exhale), because technique varies enough to move the result across a threshold.

The clinical part is where the framework asks for more than a tape. Expect questions about breathlessness on exertion and when lying flat, joint pain and what it stops you doing, sleep and snoring, reflux, menstrual or fertility history, and what has changed in the last year. Expect a blood pressure reading and blood work (fasting glucose or HbA1c, a lipid panel, liver function), because several of the eighteen criteria are laboratory findings rather than symptoms. The assessment is trying to establish not just whether these things are present but whether the adiposity is causing them.

The outcome is one of three positions, and it is worth knowing which one you are in. Anthropometric criteria not met: no obesity diagnosis, whatever BMI says on its own. Criteria met with normal organ function: preclinical obesity, which means monitoring and risk reduction rather than treatment for a disease. Criteria met with attributable organ dysfunction or functional limitation: clinical obesity, which the framework treats as a chronic illness warranting active management in its own right. Asking which of the three applies to you is a reasonable question and gives you something concrete to act on.

What the framework does not change

BMI is not abolished and the Commission did not ask for it to be. It remains a legitimate first-pass screen, the only practical measure for population surveillance, and one of the four routes to confirming excess adiposity. What it lost is the authority to diagnose on its own, which it arguably never had and was widely given anyway.

Nor does the framework retrospectively invalidate anyone's existing diagnosis or treatment. Someone already receiving care for obesity-related illness is, by the new definition, almost certainly in the clinical obesity category: the framework is a better description of what was already being treated, not a reason to stop. Equally, being told you have preclinical obesity is not a clean bill of health: it is an explicit statement of elevated future risk, and the framework recommends monitoring and risk reduction precisely because that risk is real.

And it changes nothing about the measurements themselves. Waist circumference is still taken at the midpoint between the lowest rib and the top of the hip bone, still on skin, still at the end of a normal exhale. The thresholds it feeds have become more consequential, which makes getting the technique right worth more than it was.

Why this matters practically

If your BMI has always read high while you train hard: the framework now formally agrees the number alone proves nothing. Check your waist measures and relax accordingly. If your BMI is modest but your waist has crept: the framework takes that more seriously than the old model did, because distribution is the point. Either way, the actionable habit is the same and cheap: track a waist measurement alongside weight. It is one tape pass a month, and it carries most of the new framework's information.

Frequently asked questions

Put it into practice

Run your own numbers through the BMI calculator, the waist-to-height calculator and the waist-to-hip calculator. Related reading: BMI explained, BMI for athletes and Measure your waist.

Sources

1. Rubino F, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 2025;13:221–262. doi.org/10.1016/S2213-8587(24)00316-4
2. The Lancet Diabetes & Endocrinology. Redefining obesity: advancing care for better lives. Lancet Diabetes Endocrinol 2025;13:75. doi.org/10.1016/S2213-8587(25)00004-X
3. WHO. Waist circumference and waist–hip ratio: report of a WHO expert consultation. Geneva, 2008. www.who.int/publications/i/item/9789241501491
4. Ashwell M, Gibson S. Waist-to-height ratio as an indicator of early health risk. BMJ Open 2016;6:e010159. doi.org/10.1136/bmjopen-2015-010159
5. Misra A, et al. Revised definition of obesity in Asian Indians living in India. Diabetes Metab Syndr 2025;19:102989. doi.org/10.1016/j.dsx.2024.102989
6. Ogawa W, et al.; JASSO. Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan. Endocr J 2024;71:223–31. doi.org/10.1507/endocrj.EJ23-0593